Clinical Trial Update: Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 trial comparing NovoLog (insulin aspart) vs. Fiasp (insulin aspart rapid-acting) in non-critically ill hospitalized adults with type 2 diabetes mellitus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Fiasp (insulin aspart)
• NovoLog (insulin aspart)

Snippet

Sponsor: Boston Medical Center | Conditions: Type 2 Diabetes Treated With Insulin | Phase 3 | Status: COMPLETED | Results posted: 2024-03-19